Immunotherapy has emerged as a revolutionary approach in the treatment of various malignancies. It leverages the body’s immune system to combat cancer, thereby reducing the adverse effects associated with traditional cancer treatments. This article aims to provide physicians with a comprehensive understanding of the fundamentals of immunotherapy.
Immunotherapy works by enhancing or suppressing the immune system's response. It can be classified into active, passive, and hybrid based on the approach. Active immunotherapy stimulates the immune system to work harder or smarter to attack cancer cells. In contrast, passive immunotherapies essentially provide the immune system with components, such as man-made immune system proteins, to improve the body's response.
Immunotherapy encompasses a wide array of therapeutic strategies. These include monoclonal antibodies that target specific parts of cancer cells, cancer vaccines, and non-specific immunotherapies. Additionally, checkpoint inhibitors that help the immune system recognize and attack cancer cells, and Chimeric Antigen Receptor (CAR) T-cell therapy, which involves altering T cells in the laboratory to attack cancer cells, are significant advances in this field.
Immunotherapy has been approved for the treatment of a variety of cancers, including lung, melanoma, head and neck, bladder, and kidney cancers. The effectiveness of immunotherapy can vary, with some patients experiencing complete remission while others may not respond. Factors influencing responsiveness include the type of cancer, its stage, and the patient's overall health.
Immunotherapy is a promising frontier in cancer treatment. Understanding its principles, types, and applications can equip physicians with the knowledge to make informed decisions about its use in patient care. As research progresses, the potential of immunotherapy continues to grow, underscoring the importance of staying abreast of developments in this rapidly evolving field.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation